Marine Omega‐3 Supplementation and Cardiovascular Disease: An Updated Meta‐Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants
Journal of the American Heart AssociationVol. 8, No. 19, https://doi.org/10.1161/JAHA.119.013543
Yang Hu, Frank B. Hu, and JoAnn E. Manson
Note: This study ignored:
Trials using >1800 mg of Omega-3
Ratio of DHA and EPA of th Omega-3
Bioavailability of the Omega-3 used (some suppliers claim 3X more bio-available)
Trials which added Vitamin D, Magnesium, Vitamin K, etc.
Omega-3 levels in the blood, which vary widely between people due to food consumed, weight, etc.
- Overview Cardiovascular and vitamin D
- Heart Failure and Vitamin D meta-analyses - many studies
- Heart attack ICU costs cut in half by Vitamin D – Oct 2018
- Cardiovascular calcification prevented by Omega-3, Magnesium, Vitamin K, and Vitamin D – April 2015
- Signs of low Magnesium (heart problems in this case) – Jan 2018
Items in both categories Omega-3 and Cardiovascular are listed here:
- Omega-3 reduces many aspects of heart problems - Jan 2024
- Cardiovascular problems reduced by Omega-3 - many studies
- Cardiovascular problems are prevented by Vitamin D plus Omega-3 – Feb 2023
- Omega-3 decreases heart disease and COVID: Harris and Patrick, video and transcript - Dec 2021
- Atrial Fibrillation decreased by Vitamin D or Magnesium - many studies
- Omega-3 reduced cardiovascular deaths by 16 percent (427,678 people) – March 2020
- Synthetic EPA drug recommended to FDA for Cardio (Omega-3 is 8 X better) – Nov 2019
- Omega-3 reduces heart problems by ~5 percent – meta-analysis by Heart Association Oct 2019
- Cardiovascular Prevention with Omega-3 (finally using high doses) – Sept 2019
- Few people have enough EPA (an Omega-3) to reduce heart failures – July 2019
- Another Nail in the Coffin for Fish Oil Supplements (nope) – JAMA April 2018
- Omega-3 provides many cardiovascular benefits – April 2018
- Omega-3 helps the heart, AHA class II recommendation, more than 1 gm may be needed – March 2018
- 3 days of Omega-3 before cardiac surgery reduced risk of post-op bleeding by half – RCT March 2018
- Perhaps the Omega-3 optimal level is 10 percent, not 8 – Feb 2018
- Omega-3 Cardiovascular meta-analysis has at least 5 major problems – Jan 2018
- Benefits of Omega-3 beyond heart health - LEF Feb 2018
- Higher Omega-3 index (4 to 8 percent) associated with 30 percent less risk of coronary disease (10 studies) July 2017
- Cardiovascular problems reduced by low dose aspirin and perhaps Omega-3 (also Vit K) – Sept 2017
- Omega-3 reduced time in hospital and atrial fibrillation after cardiac surgery – meta-analysis May 2016
- For every Omega-3 dollar there is a 84 dollar savings in Cardiovascular costs - Foster and Sullivan April 2016
- High dose Omega-3 probably reduces heart problems – American Heart Association – March 2017
- Health problems prevented by eating nuts (perhaps due to Magnesium and or Omega-3) – meta-analysis Dec 2016
- Omega-3 – need more than 1 gram for a short time to reduce Cardiovascular Disease – Nov 2016
- Omega-3 is vital for health, mail-in test is low cost and accurate
- Cardiovascular calcification prevented by Omega-3, Magnesium, Vitamin K, and Vitamin D – April 2015
- Atrial fibrillation sometimes treated by Omega-3 – meta-analysis Sept 2015
- Salmon intervention (vitamin D and Omega-3) improved heart rate variability and reduced anxiety – Nov 2014
- Omega-7 - in addition to Omega-3
- Omega-3 reduces Coronary Heart Disease - infographic June 2014
- Cardiovascular diseases – conflicting data on benefits of Omega-3 and vitamin D – Feb 2014
- Cardiovascular system benefits from both Omega-3 and vitamin D – Dec 2012
- Heart problems such as Afib related to little Magnesium, Omega-3, Vitamin D getting to tissues
- Omega-3 does not help heart patients – meta-analysis Sept 2012
Vitamin D and Omega-3 category starts with
CIlck here for details
Download the PDF from VitaminDWiki
Background
Whether marine omega‐3 supplementation is associated with reduction in risk of cardiovascular disease (CVD) remains controversial.
Methods and Results
This meta‐analysis included study‐level data from 13 trials. The outcomes of interest included myocardial infarction, coronary heart disease (CHD) death, total CHD, total stroke, CVD death, total CVD, and major vascular events. The unadjusted rate ratios were calculated using a fixed‐effect meta‐analysis. A meta‐regression was conducted to estimate the dose–response relationship between marine omega‐3 dosage and risk of each prespecified outcome. During a mean treatment duration of 5.0 years, 3838 myocardial infarctions, 3008 CHD deaths, 8435 total CHD events, 2683 strokes, 5017 CVD deaths, 15 759 total CVD events, and 16 478 major vascular events were documented. In the analysis excluding REDUCE‐IT (Reduction of Cardiovascular Events with Icosapent Ethyl‐Intervention Trial), marine omega‐3 supplementation was associated with significantly lower risk of
- myocardial infarction (rate ratio [RR] [95% CI]: 0.92 [0.86, 0.99]; P=0.020),
- CHD death (RR [95% CI]: 0.92 [0.86, 0.98]; P=0.014),
- total CHD (RR [95% CI]: 0.95 [0.91, 0.99]; P=0.008),
- CVD death (RR [95% CI]: 0.93 [0.88, 0.99]; P=0.013), and
- total CVD (RR [95% CI]: 0.97 [0.94, 0.99]; P=0.015).
Inverse associations for all outcomes were strengthened after including REDUCE‐IT while introducing statistically significant heterogeneity. Statistically significant linear dose–response relationships were found for total CVD and major vascular events in the analyses with and without including REDUCE‐IT.
Conclusions
Marine omega‐3 supplementation lowers risk for myocardial infarction, CHD death, total CHD, CVD death, and total CVD, even after exclusion of REDUCE‐IT. Risk reductions appeared to be linearly related to marine omega‐3 dose.
What Is New?
- We updated previous meta‐analyses by adding 3 recent large randomized controlled clinical trials, increasing sample size by 64%.
- Marine omega‐3 supplementation significantly lowered risk for most cardiovascular end points, even after excluding a trial testing very high‐dose supplementation.
- Risk reductions were linearly associated with dose of marine omega‐3 supplementation.
What Are the Clinical Implications?
Daily marine omega‐3 supplementation is effective in lowering risk for coronary and most other cardiovascular end points, including myocardial infarction, coronary heart disease death, total coronary heart disease, cardiovascular disease death, and total cardiovascular disease; no benefits, however, were found for stroke.
Greater cardiovascular benefits may be achieved at higher doses of marine omega‐ 3 supplementation.
| 3606 visitors, last modified 03 Oct, 2019, |